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Abstract
Background: Patients experiencing large thermal injuries are susceptible to opportunistic infections that can delay
recovery and lead to sepsis. Dendritic cells (DC) are important for the detection of pathogens and activation of the
innate and acquired immune responses. DCs are significantly decreased in burn patients early after injury, and the
development of sepsis is associated with persistent DC depletion. In a murine model of burn wound infection,
the enhancement of DCs after injury by treatment with the DC growth factor Fms-like tyrosine kinase-3 ligand (FL)
enhances neutrophil migration to infection, improves bacterial clearance, and increases survival in a DC-dependent
manner. FL expands the production of both conventional DCs (cDC) and plasmacytoid DCs (pDC). It has been
established that cDCs are required for some of the protective effects of FL after burn injury. This study was
designed to determine the contribution of the pDC subset.
Methods: Mice were subjected to full-thickness scald burns under deep anesthesia and were provided analgesia.
pDCs were depleted by injection of anti-plasmacytoid dendritic cell antigen-1 antibodies. Survival, bacterial
clearance, and neutrophil responses in vivo and in vitro were measured.
Results: Depletion of preexisting pDCs, but not FL-expanded pDCs, abrogated the beneficial effects of FL on
survival, bacterial clearance, and neutrophil migration in response to burn wound infection. This requisite role
of pDCs for FL-mediated enhancement of neutrophil migratory capacity is not due to direct effects of pDCs on
neutrophils. cDCs, but not pDCs, directly increased neutrophil migratory capacity after co-culture.
Conclusions: The protective effects of FL treatment after burn injury are mediated by both pDCs and cDCs.
Pharmacological enhancement of both DC subtypes by FL is a potential therapeutic intervention to enhance
immune responses to infection and improve outcome after burn injury.
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Background
Patients experiencing large thermal injuries are suscep-
tible to opportunistic infections, sepsis, and associated
complications. Despite the widespread use of antibiotics,
infection remains the leading cause of death among
severely burned patients, necessitating the need of
immune-modulating therapies [1]. Wounds and invasive
instrumentation placed during acute care increase the
risk of exposure to microorganisms. Furthermore, cells
of both the innate and adaptive immune systems often
experience debilitated or dysregulated functions follow-
ing burn injury. For example, neutrophil chemotaxis is
impaired in burn patients [2, 3]. Natural Killer (NK) cells
have diminished killing capabilities, and macrophages
can become inflammatory and lose phagocytic properties
and the ability to eliminate foreign pathogens [4, 5].
Additionally, there is a decrease in the production of
cytokines such as IFN-γ, IL-12, and IL-2 that are import-
ant mediators of Th1 responses in acquired immunity
[6]. Dendritic cells (DCs) are important for the initiation
of both the innate and acquired immune responses,
through antigen presentation and secretion of IL-2,
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IL-12, IFN-γ and other cytokines that activate leukocytes
to respond to infection. Burn patients have a significant
decrease in circulating DCs early after injury and
development of sepsis is associated with persistent DC
depletion over the first 2 weeks after injury [7]. Thus,
restoration of DC numbers and functions after burn
injury may restore appropriate immune responses and
prevent burn-associated infections.
Fms-like tyrosine kinase-3 ligand (FL) has been used
experimentally to increase DC numbers and functions in
models of severe burn injury [8]. The FL receptor, Fms-
like tyrosine kinase-3 receptor (Flt3R), is expressed by
multipotent progenitor cells and common lymphoid pro-
genitor cells in the bone marrow. It is part of the tyrosine
kinase class III family, and is essential for DC develop-
ment. Binding of FL to Flt3R triggers progenitor cell pro-
liferation and subsequent differentiation. Differentiation
into non-DC cell types is associated with loss of Flt3R
expression; however, DCs maintain expression of Flt3R
after differentiation. In vivo administration of exogenous
FL induces a significant expansion of both conventional
DCs (cDCs) and plasmacytoid DCs (pDCs) in blood and
lymphoid tissues of humans and mice [9–12]. Following
thermal injury in mice, FL treatment increases DC num-
bers, enhances DC function, and increases survival in
response to Pseudomonas aeruginosa infection in a DC-
dependent manner. Enhanced bacterial clearance and
survival are also dependent upon neutrophils, whose mi-
gration to sites of infection is increased, in a DC-
dependent manner, by FL treatment [13]. The effects of
FL on neutrophils are indirect and mediated by FL-
enhanced DCs. Neutrophils do not express the Flt3R and
FL enhancement of neutrophil migratory capacity is
absent in DC-depleted mice. Furthermore, the direct ex-
posure of neutrophils to FL-treated DCs in co-cultures
enhances the chemotactic capacity of neutrophils [13].
Thus, the enhancement of DCs by FL treatment after burn
injury is responsible for the improved neutrophil-mediated
clearance of subsequent infections.
DCs consist of two principal and distinct subtypes.
cDCs (MHC II+/CD11chigh/B220−) are recognized as
major initiators of effector cell activation in response to
infection, through antigen recognition, cytokine produc-
tion, and antigen presentation. pDCs (mPDCA-1+/B220
+/ CD11clow in mice), mostly known for IFN-α produc-
tion in response to viral infection, can also induce
immune responses [14]. pDCs are mobilized by inflam-
mation and can enter lymph nodes directly from the
circulation through high endothelial venules [15]. Al-
though steady state pDCs are not as efficient as cDCs at
the activation of T cells, activated pDCs can present
antigen and induce T cell polarization [16]. There is
increasing evidence that pDCs also play an important
role in promoting cDC functions that activate immune
responses. For example, pDCs are required by cDCs for
efficient activation of T cells. By CD2-CD2L interactions,
pDCs contact cDCs. Through subsequent CD40L-CD40
interactions, pDCs can help cDCs to generate anti-viral
cytotoxic T cells and to produce IL-12 in response to
CpG stimulation [17, 18].
Prior studies examining the effects of FL and DCs on
responses to infection after burn injury focused on total
(CD11c+) DCs and did not distinguish between the DC
subtypes. This study was designed to investigate the
contribution of pDCs to the protective effects of FL
treatments after burn injury. Here we report that the
presence of pDCs during in vivo treatment is required
for FL to increase resistance to infection after burn
injury. Depletion of pre-existing pDCs (prior to FL-
induced expansion) in a murine burn wound infection
model leads to significant loss of protective functions
otherwise conferred by FL treatment. Furthermore, the
FL-induced in vivo enhancement of neutrophil migration
and bacterial clearance is dependent on pDCs, but
through indirect effects on neutrophils.
Results
FL-mediated resistance to burn wound infection is
dependent upon the presence of pDCs during treatment
As previously reported [8], treatment of mice with FL
after burn injury significantly improved survival follow-
ing a lethal P. aeruginosa burn wound infection. Survival
in control (LR)-treated mice was 20% at 12 days post-
inoculation, whereas survival in FL-treated mice was
71% (Fig. 1a). However, elimination of pDCs by injection
of anti-PDCA-1 antibodies prior to FL treatment re-
duced survival to 25%. Injection of control IgG prior to
initiation of FL treatment did not affect survival, which
was 67% in this antibody control group. However,
survival in mice depleted of pDCs after FL treatment,
during wound infection, was 65% and similar to that in
FL-treated control mice. Flow cytometric analysis of
pDC markers (pDCA-1, B220) confirmed effective de-
pletion of pDCs under both protocols (pDC depletion
prior to and after FL treatment, Fig. 1b). This indicates
that pre-existing pDCs, and not FL-expanded DCs,
are necessary for FL to increase survival upon subse-
quent infection.
Increased survival in FL-treated mice is associated
with a decrease in systemic dissemination of bacteria
from infected burn wounds [8]. Since mortality was
increased in FL-treated mice that had been depleted
of pre-existing pDCs, bacterial dissemination after
wound infection was examined in this group and
compared to that in the control IgG- and FL-treated
group. As expected, bacterial counts in the spleens of
pDC-depleted FL-treated mice were significantly
higher than in the control FL-treated mice (Fig. 2).
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Bacterial counts in the control FL group were
detected in only one mouse and were negligible, but
100% of the pDC-depleted mice had positive cul-
tures. Consistent with our earlier reports where FL
minimally reduces bacterial burden at the site of
infection (2.5X reduction in wound bacterial counts)
but prevents the infection from spreading [19], FL
treatment did not eliminate the large inoculum from
the wound, but did prevent systemic dissemination.
pDC depletion prior to FL treatments caused a 2.5X
increase in wound bacterial counts, but a 400X in-
crease in bacterial counts in the spleen (Fig. 2). FL
appears to increase the ability of the immune system
to contain the infection locally in a pDC-dependent
manner.
pDCs are required for FL-mediated enhancement of
neutrophil response to infection
The primary mechanism by which FL treatments protect
against burn-associated sepsis is through enhancement
of neutrophil responses to infection, resulting in limited
dissemination and accelerated resolution of infection
[13]. As previously reported, treatment of mice with FL
after burn injury significantly increased the numbers of
neutrophils responding to burn wound infection. At
3 days after wound inoculation, the percentages of neu-
trophils in the wound-draining lymph nodes were higher
in mice treated with FL, compared to all other groups
(Fig. 3a). Additionally, total numbers of neutrophils were
significantly higher in wound-draining lymph nodes of
FL-treated mice (~2.3-fold) compared to LR-treated
Fig. 1 pDCs are essential for FL-mediated protection against a burn wound infection. a Timeline shows experimental protocols: Mice received
burn injury on day 1 and FL treatment on days 2–5. Mice either received pDC depletion antibodies on days 1 and 2 (anti-pDC + FL) or on days 4
and 5 (FL + anti-pDC). IgG control mice received nonspecific IgG on days 1 and 2. Wounds were inoculated on day 5. Survival was monitored for
12 days following inoculation. *significantly different from FL, FL + anti-pDC, p≤0.05, n = 9–17 mice per group. b Spleen and lymph nodes cells
were stained and analyzed by FACS to confirm depletion of pDCs by anti-pDCA1 antibodies. Histograms are representative of staining in 3 mice/
group and show PDCA-1 staining (light grey highlighted area) in CD45 (B220) + cells
Fig. 2 pDCs are required for FL to prevent bacterial dissemination from the wound. Spleens and wounds were harvested 3 days following
wound inoculation, homogenized and cultured for determination of bacterial counts. Numbers over the graphs represent the number of mice
with positive tissue cultures of the total number examined. *significantly different from IgG + FL, p≤0.05, n = 5 mice per group
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mice, as were levels of myeloperoxidase (MPO) (~3.8-
fold). However, pDC depletion prior to FL treatment
reduced MPO and the numbers and percentages of
neutrophils in the lymph nodes to levels that were no
longer significantly different from the control treatment
(LR) group. This indicates that pre-existing pDCs must
be present during FL treatment for the subsequent
enhancement of neutrophil responses to wound infec-
tion initiated several days later. Neutrophils in infected
wounds were approximately 2-fold higher after FL
treatment compared to LR treatment, but not if pDCs
had been depleted prior to FL treatment. While the dif-
ferences between treatment groups were not statistically
significant for wound measurements (p = .07), the trend
was the same as that seen in the wound-draining lymph
nodes (Fig. 3b). The opposite trend was observed in the
spleen. In response to wound infection, there was a con-
comitant decrease in spleen neutrophils in FL-treated
mice (~3-fold compared to LR), as neutrophil migration
to infected wounds increased, and both trends were
Fig. 3 pDCs are required for FL to increase neutrophil responses to infection. Mice were injected with control IgG or anti-pDC antibodies prior to
initiation of FL or LR control treatment. Tissues were harvested 3 days following wound inoculation. a The percentages (top panel) and numbers
(middle panel) of Ly6G+ neutrophils and MPO levels (bottom panel) in the wound-draining lymph nodes. *significantly different from both LR
groups, p≤0.05, (b) Percentages of Ly6G+ neutrophils in wounds and spleens following infection are shown. *significantly different from IgG + LR,
p≤0.05. n = 3–6 mice per group
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attenuated if pDCs were not present during treatment.
The effects of pDC depletion during FL treatment were
specific for neutrophils, as overall cellularity and cDC
numbers were not similarly decreased by pDC depletion.
As previously reported [19, 20], treatment of mice with
FL after burn injury significantly increased overall cellu-
larity and the numbers of cDCs in wound-draining
lymph nodes (Fig. 4). Lymph nodes of FL-treated mice
had significantly more leukocytes (~1.6-fold) and DCs
(~2.5-fold) than lymph nodes of LR-treated mice, an
effect that was not altered by pDC depletion.
Enhanced neutrophil responses to infection in FL-
treated mice is associated with an increased migratory
capacity of neutrophils, demonstrated by greater in vitro
chemotaxis of neutrophils freshly harvested from FL-
treated mice compared to control-treated mice [13]. As
shown in Fig. 5a, chemotaxis to fMLP was significantly
greater in neutrophils that had been freshly harvested
from mice treated with FL (IgG + FL) compared to neu-
trophils from LR (IgG + LR)-treated mice. However, if
pDCs had been eliminated prior to initiation of FL treat-
ment in vivo, subsequent in vitro chemotaxis of isolated
neutrophils was no longer increased by FL.
In vitro, DCs can directly enhance neutrophil migra-
tory capacity. Specifically, the ability of neutrophils to
migrate to a common stimulus in vitro is significantly
increased after exposure to DCs in overnight culture. FL
further enhances this effect of DCs on neutrophil migra-
tory capacity [13]. To determine if the pDC subset may
directly enhance neutrophil migration, we similarly co-
cultured pDCs with neutrophils prior to assessment of
neutrophil migration. Co-culture of neutrophils with
pDCs did not enhance neutrophil migration (Fig. 5b).
Migration of neutrophils exposed to pDCs from FL-
treated mice was not different when compared to that of
neutrophils that had not been previously cultured with
pDCs. In fact, exposure of neutrophils to pDCs from
LR-treated mice appeared to slightly decrease neutrophil
migration capacity, but the difference between groups
was not statistically significant.
The finding that pDCs and cDCs are both necessary
for FL enhancement of neutrophil response to infection
in vivo [13], yet pDCs do not directly enhance neutro-
phil migration, indicates that FL induces effects in pDCs
that indirectly modulate neutrophils. It has been re-
ported that pDCs can act as “helper” cells to cDCs to
enhance cDC-initiated immune responses [17, 18]. We
therefore investigated the possibility that pDCs may
“help” cDCs to enhance neutrophil migration capacity.
As demonstrated in Fig. 5c, and as previously reported,
co-culture of neutrophils with CD11c+ DCs from control
(LR)-treated mice significantly increased subsequent
neutrophil chemotaxis (2.7-fold) when compared to neu-
trophils that had not been previously cultured with DCs.
Prior incubation of neutrophils with CD11c+ DCs from
FL-treated mice further increased their migration 1.8-
fold when compared to neutrophils exposed to LR cDCs,
and 5-fold when compared to migration of neutrophils
that had not been previously cultured with DCs. Deple-
tion of pDCs at the initiation of in vivo FL treatment did
not affect the ability of the remaining cDCs to enhance
neutrophil chemotaxis. Depletion of pDCs in LR-treated
mice actually increased the ability of cDCs to promote
neutrophil migration, but had no effect on FL enhance-
ment of migration. These data indicate that pDCs do
not serve as helpers of cDCs in their function of modu-
lating neutrophil migration capacity.
Discussion
In earlier studies, we found that FL has the potential to
be used as a prophylactic treatment after burn injury to
increase resistance to subsequent infections. When ad-
ministered before or after burn injury, FL increases DC
numbers, restores Th1 cytokine responses, prevents bac-
terial growth, dissemination of infection and systemic in-
flammation, and increases survival following infection
[8, 20]. A recent study shows that FL treatment also en-
hances adaptive immune responses through attenuation
of T cell dysfunction after burn wound sepsis [21]. FL-
altered DCs have been shown to directly induce several
Fig. 4 pDC depletion does not alter total leukocyte or cDC numbers. Mice were treated as in Fig. 3. *significantly different from both LR groups,
p≤0.05, n = 5 mice per group
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of these beneficial alterations. Adoptive transfer of
CD11c+ DCs from FL-treated mice significantly in-
creases survival after wound infection in non-treated re-
cipient mice whereas equivalent numbers of DCs from
control-treated mice do not improve survival. Con-
versely, depletion of CD11c+ DCs prevents FL-mediated
protection against infection [13]. However, FL stimulates
the production of both pDCs and cDCs, distinct popula-
tions of cells that contribute to immune responses by
distinct mechanisms. As pDCs in mice express low
levels of CD11c, it is possible that pDCs, although com-
paratively lower in numbers than cDCs, could have
contributed to the previously reported effects of FL.
Therefore, anti-mouse pDCA-1 was used here to specif-
ically deplete pDCs, but not cDCs, during FL treatment.
We found that pDCs are required for the beneficial ef-
fects of FL in vivo, but within a different time frame
than the requirement for cDCs. Specifically, we previ-
ously observed that either depletion of pre-existing
CD11c+ DCs at the start of FL treatment or depletion of
FL-expanded CD11c+ DCs after FL treatment, at the
time of infection, abrogates the protective effects of FL
in burn-injured mice [13]. However, we show here that
the pDC subset is not required at the time of infection,
but is required at the time of treatment for FL to en-
hance neutrophil responses to infection, bacterial clear-
ance, and survival after wound infection (Figs. 1, 2 and
3). This indicates that FL has early effects on pre-
existing (prior to FL-induced expansion) pDCs that im-
pact subsequent responses to infection, perhaps through
the priming or activation of other immune cells.
A primary mechanism by which FL enhances resist-
ance to infection after burn injury is through enhance-
ment of neutrophil migration to sites of infection [13].
This was confirmed here, as treatment of mice with FL
increases the numbers of neutrophils responding to burn
wound infection, indicated by the increased presence of
neutrophils and higher levels of MPO in the wound-
draining lymph nodes of infected mice treated with FL
(Fig. 3). Preexisting pDCs are required during FL treat-
ment for these in vivo effects, as their depletion abol-
ishes the effects of FL on neutrophil responses. At the
same time, splenic neutrophils significantly decrease
during infection in FL-treated mice, and this is also
dependent on preexisting pDCs. This suggests that
splenic neutrophils are somehow primed by FL in a
pDC-dependent manner for a rapid response to infec-
tion. Indeed, freshly isolated neutrophils from FL-treated
mice show increased chemotaxis in vitro when com-
pared to neutrophils isolated from LR-treated mice, but
only if pDCs were present during in vivo FL treatment
(Fig. 5a). While the mechanism by which preexisting FL-
stimulated pDCs prime neutrophils for rapid migration
is not known, our data indicate that this is mediated
Fig. 5 pDCs are required, indirectly, for FL-mediated enhancement of
neutrophil chemotaxis. a Neutrophils were harvested from burned
mice treated with FL in the presence and absence of pDCs (IgG
+ FL, anti-pDC + FL) and migration towards fMLP was measured.
*significantly different from other groups, p <0.05, n = 6–15. b
PDCA-1+ pDCs were isolated from burned mice that had been
treated in vivo with control LR or FL and were co-cultured overnight
with neutrophils that had been harvested from burned, non-treated
mice. Migration to fMLP was subsequently assessed. n = 5–15. c CD11c
+ DCs were isolated from burned mice that had been depleted of
pDCs or not at the start of FL treatment as in Fig. 1. Neutrophils were
harvested from burned mice and co-cultured with DCs overnight prior
to measurement of migration towards fMLP. *significantly different
from all other groups, p <0.05, n = 4–6
Bae et al. BMC Immunology  (2017) 18:9 Page 6 of 9
indirectly. Co-culturing neutrophils with pDCs does not
increase subsequent migration (Fig. 5b), whereas the dir-
ect exposure of neutrophils to cDCs does increase neu-
trophil migratory capacity, an effect that is enhanced by
FL (Fig. 5c). The finding that pDC depletion abrogates
the effects of FL on neutrophil responses in vivo (Fig. 3)
indicates that cDCs are not able to effectively enhance
neutrophil migratory capacity if pDCs are not present
during treatment.
pDCs have been shown by others to enhance some
cDC functions. Specifically, cDC interactions with pDCs
via CD40:CD40 ligand on cDCs and pDCs, respectively,
are requisite for CpG DNA-stimulated IL-12 production
by cDCs [18]. As both pDCs and cDCs are required for
FL enhancement of neutrophil migration to infection in
vivo [13], and cDCs but not pDCs directly enhance
neutrophil migratory capacity, we reasoned that pDCs
may prime or signal cDCs in their capacity as enhancers
of neutrophil migration. However, depletion of pDCs at
the start of FL treatment, which abrogated enhanced
neutrophil responses in vivo, did not affect the subse-
quent ability of cDCs to directly enhance neutrophil
chemotaxis in vitro (Fig. 5c). Therefore, the mechanisms
remain to be identified. It should be noted that the con-
sequence of pDC depletion was specific and not a global
reduction in cellular responses to infection as cDCs and
overall cellularity in the wound draining lymph nodes
were not similarly reduced by prior pDC depletion
(Fig. 4). Also, anti-PDCA-1 antibodies do not directly
deplete neutrophils themselves and do not cause a de-
crease in neutrophil numbers in the absence of infection.
Additionally, the effects of pDCs on neutrophil re-
sponses are specific to FL treatment, as depletion of
pDCs in LR-treated mice does not decrease neutrophil
responses to infection in vivo (Fig. 3). This indicates that
activation of pDCs by FL induces unique responses that
influence neutrophil migration in vivo.
This study is limited by the lack of an identified under-
lying mechanism. The unusual time frame during which
pDC presence in vivo is required for FL to protect
against later infections suggests that the underlying
mechanisms are likely complex and challenging to dis-
sect. Specifically, pDCs were depleted on day 1 and FL
treatments initiated on day 2 (Fig. 1), and wounds were
not inoculated until day 5. The effect on neutrophil re-
sponses to infection, specifically, decreased neutrophil
presence in wound-draining lymph nodes, was demon-
strated 7 days after pDC depletion (Fig. 3). A possible
explanation of these findings is that FL directly stimu-
lates pre-existing pDCs early during treatment to pro-
duce a chemotactic factor that mobilizes neutrophils
and/or cDCs and facilitates neutrophil-cDC interactions.
In this scenario, the depletion of cDCs would be suffi-
cient to abolish the protective effects of FL because
neutrophil migratory capacity would not be enhanced
via cDC-neutrophil interactions [13]. Likewise, the de-
pletion of pDCs in vivo would also be sufficient to pre-
vent the effects of FL, as the signal that facilitates cDC-
neutrophil interactions in vivo would not be induced (as
in Fig. 3). However, co-culture of neutrophils with cDCs
would still enhance neutrophil migratory capacity as this
is not dependent on pDCs (as in Fig. 5c). While the data
presented here are consistent with that scenario, further
studies are needed to dissect this complex in vivo re-
sponse to infection and FL treatment. We have investi-
gated the potential contribution of individual cytokines
that are known to play a role in neutrophil mobilization
and maturation/activation. While we found that FL has
effects on some of these mediators, it also modulates the
production of numerous other cytokines, especially
those associated with Th1 responses during infection
[20]. To date, we have been unable to identify a specific
mediator that is induced by FL only in the presence of
preexisting pDCs. Similarly, we have been unable to
identify neutrophil phenotypes that are induced by FL
only in the presence of pDCs. The early responses to
burn injury are complex and dynamic and involve the
mobilization of numerous innate immune cells, includ-
ing neutrophils and DCs, from multiple tissues to sites
of injury [22]. Additionally, there is a systemic inflamma-
tory response to burn injury, where numerous mediators
are released into the circulation [23]. Therefore, it is
possible that multiple factors induced by FL and burn
injury may act synergistically to induce these beneficial,
pDC-dependent effects on neutrophil responses to infec-
tion. Future studies will investigate multiple factors that
may act in concert to mediate these effects of FL.
Conclusions
Although the underlying mechanisms by which pDCs
indirectly mediate the protective effects of FL have yet
to be identified, this study provides some novel findings.
The ability of FL to enhance neutrophil responses to
burn wound infection, bacterial clearance, and survival
is dependent upon both pDCs and cDCs. While pDCs
are required for FL to enhance neutrophil responses in
vivo, pDCs do not directly enhance the capacity of neu-
trophils to migrate, and do not serve as “helper” cells to
cDCs in this capacity. Regardless of the mechanisms, the
significant protection against burn wound infection
afforded by FL supports the potential utility of FL as a
treatment to decrease infections in burn patients.
Methods
Mice
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee at the University
of Texas Medical Branch and meet the National
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Institutes of Health guidelines for the care and use of ex-
perimental animals. Male, BALB/c mice, 6–10 weeks of
age, were given a preemptive dose of buprenorphine
(0.1 mg/kg, s.c.), then deeply anesthetized with isofluor-
ane 30 min later. Dorsal and lateral surfaces were shaved
with clippers, and mice were placed on their backs in a
protective template that exposed approximately 35% of
the total body surface area TBSA. A non-lethal full-
thickness injury was induced by immersion of the
exposed skin in 97–99 °C water for 10 s, and fluid resus-
citation (lactated Ringers solution, LR, 2 cc, i.p.) was
administered. Mice were monitored twice daily for signs
of discomfort and administered buprenorphine up to
every 12 h if needed. Recombinant FL was provided by
Celldex Therapeutics (Needham, MA), and was injected
once daily (10 μg in 0.1 cc LR, i.p.). Control treatment
mice received the same volume of LR according to the
same protocol. FL treatment was initiated on either the
day of or after burn injury and continued for 4 days. We
have demonstrated that FL treatments can be started im-
mediately after injury or several days later with similar
efficacy [19]. Anti-plasmacytoid DC antigen-1 (pDCA-1,
or anti-pDC, Miltenyi Biotec) or control IgG was
injected for two consecutive days (500 μg, i.p.), begin-
ning on the day before FL treatment (early depletion) or
on the last day of FL treatment (late depletion). At the
end of experiments, mice were humanely euthanized
according to the AVMA Guidelines of Euthanasia, via
cervical dislocation under isoflurane (5% in air) anesthesia.
Infection
P. aeruginosa (ATCC #19660, Manassas, VA), a common
source of wound infections in burn patients, was grown
in tryptic soy broth, diluted in sterile saline, and applied
topically to the surface of the burn wound. Wounds
were inoculated 4 or 5 days after burn injury with 104 or
5x104 CFU, respectively. Survival was monitored for
14 days post-inoculation. For determination of cfu/g tis-
sue wet weight, spleen and skin samples were weighed,
homogenized in sterile saline and serial dilutions plated
and incubated overnight on tryptic soy agar.
In vitro chemotaxis
Minced spleens and wound-draining lymph nodes (axil-
lary, inguinal) were mechanically dissociated and passed
through a 70 μm strainer. Red blood cells were lysed
(RBC Lysing Buffer Hybri-Max, Sigma-Aldrich), cell sus-
pensions were washed, and neutrophils were isolated
using Ly6G (1A8) microbeads and Miltenyi magnetic
separation columns according to manufacturer’s direc-
tions (Miltenyi Biotech). Neutrophils were plated in the
upper chambers of polycarbonate transwell filters (5 μm
pores, Thermo Fisher Scientific) with 10−6 M fMLP
(Sigma) in the lower chamber, and incubated at 37 °C
for 2–3 h. Cells in the lower chamber were detached by
addition of 7 mM EDTA (Sigma) and counted using a
hemocytometer and trypan blue. In co-culture experi-
ments, CD11c+ DCs or PDCA-1+ pDCs were co-
cultured with neutrophils overnight in RPMI-1640
supplemented with 10% fetal bovine serum and antibi-
otics at a ratio of (1:10 DC to neutrophils) prior to the
chemotaxis assay.
Flow cytometry
Spleen and lymph node single cells suspensions were
prepared as described above. Wound cells were liberated
by incubation in 1 mg/ml collagenase D for 30 min at
37 °C in a shaking incubator. Single cell suspensions
were incubated with 0.5 mg/ml Fc block and 0.5 μg
fluorescence-conjugated antibodies against specific sur-
face proteins for 20 min at 4 °C, then washed in PBS.
Cells were fixed and permeabilized using Cytofix/Cyto-
perm (BD Biosciences) according to manufacturer’s in-
structions, washed in BD Perm/Wash, then incubated
with 0.5 μg fluorescence-conjugated antibodies. After
washing, cells were analyzed on a Guava® easyCyte 8HT
flow cytometer, using InCyte software (Millipore). Anti-
bodies against B220, CD11c, and Ly6G were from BD.
Myeloperoxidase (MPO)
Wound-draining lymph nodes were homogenized in
lysis buffer (200 mM NaCl, 5 mM EDTA, 10 mM Tris,
10% glycerol, 1 mM PMSF). MPO was measured by
ELISA per manufacturer’s instructions (Cell Sciences).
Statistics
Analyses were performed using GraphPad Prism 6.00 for
Windows, GraphPad Software, La Jolla California USA,
www.graphpad.com. Survival curves were estimated by
Kaplan-Meier method and compared by log-rank test.
Unpaired, two-tailed Student’s t-tests compared two
groups. Multiple groups were analyzed by ANOVA/
Tukey-Kramer multiple comparisons test. p ≤ 0.05 was
considered significant.
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